Morgan Stanley
ACXP icon

Morgan Stanley’s Acurx Pharmaceuticals ACXP Stock Holding History

Morgan Stanley’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.1K Hold
6,500
– – ﹤0.01% 6656
2025
Q4 		$16.2K Buy
6,500
+1,190
+22% +$5.71K ﹤0.01% 6759
2025
Q3 		$22.8K Hold
5,310
– – ﹤0.01% 6648
2025
Q2 		$54.2K Hold
5,310
– – ﹤0.01% 6331
2025
Q1 		$41.4K Hold
5,310
– – ﹤0.01% 6333
2024
Q4 		$86.4K Buy
5,310
+3,000
+130% +$90.3K ﹤0.01% 6111
2024
Q3 		$87.8K Sell
2,310
-10
-0.4% -$423 ﹤0.01% 6054
2024
Q2 		$104K Buy
2,320
+1,000
+76% +$44K ﹤0.01% 5942
2024
Q1 		$64.7K Sell
1,320
-300
-19% -$19.5K ﹤0.01% 6128
2023
Q4 		$124K Buy
1,620
+870
+116% +$65.7K ﹤0.01% 6093
2023
Q3 		$22.5K Buy
+750
New +$28.7K ﹤0.01% 6443
2022
Q1 		– Hold
0
– – – 7939
2021
Q4 		– Hold
0
– – – 7954

Other funds holding ACXP

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Morgan Stanley's ACXP Position: Q1 2026 in Review

Morgan Stanley held its Acurx Pharmaceuticals (ACXP) position steady in Q1 2026 at 6,500 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6656.

Morgan Stanley first reported a position in ACXP in Q3 2023 and has held it in 11 quarters since. The position peaked at $124K in Q4 2023. 21 funds tracked by Wall St. Rank hold ACXP as of Q1 2026.

  • Morgan Stanley held 6,500 shares of Acurx Pharmaceuticals worth $24.1K as of Q1 2026.
  • Morgan Stanley left its Acurx Pharmaceuticals share count unchanged in Q1 2026.
  • Acurx Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6656 holding.
  • Morgan Stanley first reported a position in Acurx Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Morgan Stanley's Acurx Pharmaceuticals position peaked at $124K in Q4 2023.
  • 21 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.